McBroom & Associates LLC Decreases Stock Position in Zoetis Inc. $ZTS

McBroom & Associates LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 72.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 7,849 shares of the company’s stock after selling 21,006 shares during the period. McBroom & Associates LLC’s holdings in Zoetis were worth $988,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $31,000. Finally, Holos Integrated Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at approximately $32,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.1%

ZTS stock opened at $117.83 on Friday. The company has a 50 day moving average price of $122.71 and a two-hundred day moving average price of $128.09. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a market capitalization of $49.74 billion, a P/E ratio of 19.57, a PEG ratio of 1.80 and a beta of 0.98. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the prior year, the company posted $1.40 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of analyst reports. Bank of America increased their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Piper Sandler reissued a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.